A Combinatorial Approach to Enhance Production of Monoclonal Antibodies

Monoclonal antibodies—therapeutic proteins used to treat cancer, arthritis, and other diseases—cost so much to manufacture that health systems often struggle to afford them. This project alters the cells that produce these antibodies so that each cell churns out far more of the drug, cutting production costs. The problem is straightforward: making biologics like Herceptin requires growing engineered cells in expensive nutrient broths, and yields are often low. That expense gets passed to patients and providers. By tweaking the cellular machinery—for instance, boosting the pathways that assemble and secrete antibodies—the researchers aim to get more drug from each batch without building bigger factories. If successful, the work could lower the price of existing antibody therapies and make it financially viable to develop new ones for conditions where cost currently blocks access. The impact would ripple through supply chains: cheaper production means more doses per facility, shorter manufacturing timelines, and potentially wider global distribution. This is applied biotechnology, not fundamental science—the goal is a practical, near-term improvement in how biologics are made, not a conceptual breakthrough.